NCT03801746View on ClinicalTrials.gov

Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 20, 2018

Primary Completion Date

August 15, 2018

Study Completion Date

August 15, 2018

Conditions
Drug Interaction Potentiation
Interventions
DRUG

vadadustat

Oral dose 300 mg

DRUG

Rifampin

IV Rifampin

DRUG

Probenecid

Oral Probenecid

DRUG

Cyclosporins

Oral Cyclosporine

Trial Locations (1)

G1P A02

inVentiv Health Clinique Inc., Québec

Sponsors
All Listed Sponsors
lead

Akebia Therapeutics

INDUSTRY

NCT03801746 - Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin | Biotech Hunter | Biotech Hunter